• Turn Therapeutics highlighted GX-03, a topical, non-systemic immunomodulator targeting IL-36 and downstream cytokines, with initial focus on moderate-to-severe atopic dermatitis.
• Phase 2 randomized trial in atopic dermatitis remains in progress; topline results are expected in Q4 2026.
• Stage 1 completed in June 2026 with 50 patients; Stage 2 targets about 120-135 patients in an adaptive, vehicle-controlled design.
• Interim subgroup showed Week 4 vIGA-AD success of 61.5% for GX-03 versus 8.3% for vehicle; p=0.01.
• Pipeline milestones include a Type B FDA meeting in Q4 2026; Phase 3 initiation targeted for mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.